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Abstract: Hypertension is a major risk factor for cardiovascular disease that contributes to the 
premature death of millions of people each year, and identiﬁ  cation and treatment of hypertension 
continues to be a challenge. Guidelines recommend that many patients will require two or more 
antihypertensive agents from different classes. Combining an angiotensin II receptor blocker 
(ARB) with hydrochlorothiazide (HCTZ) has been shown in clinical studies to increase the 
antihypertensive efﬁ  cacy of both agents compared with either agent alone. This review covers 
several clinical trials and aims to examine several aspects of the efﬁ  cacy of the combination of 
olmesartan and HCTZ, including dose-responsiveness, long-term efﬁ  cacy, goal rate achieve-
ment, and efﬁ  cacy in patients with moderate to severe hypertension. The results presented here 
demonstrate that olmesartan is effective when added to HCTZ monotherapy or when HCTZ 
is added to olmesartan monotherapy, both over the short and long term. Moderate to severe 
hypertension responds well to olmesartan/HCTZ combination therapy, and the great majority 
of patients are able to achieve recommended blood pressure targets. Thus olmesartan/HCTZ is 
a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy 
in those who require large reductions in diastolic blood pressure or systolic blood pressure to 
achieve goal blood pressure.
Keywords: hypertension, olmesartan medoxomil; hydrochlorothiazide, angiotensin II receptor 
blocker, thiazide diuretic
Introduction
Hypertension is a major risk factor for cardiovascular disease that contributes to the 
premature death of millions of people each year (Chobanian et al 2003). The relation-
ship between blood pressure and morbidity and mortality is linear (Lewington et al 
2002; Chobanian et al 2003); thus, the greater the reduction in blood pressure the greater 
the reduction in risk (Hansson et al 1998). Well deﬁ  ned targets for blood pressure 
have been established in treatment guidelines (Chobanian et al 2003; Whitworth 2003; 
Mancia et al 2007), and state that blood pressure targets should be 140/90 mmHg, 
or 130/80 mmHg for patients with diabetes or renal disease.
While the percentage of patients meeting these targets has increased in recent years 
(Chobanian et al 2003), identiﬁ  cation and treatment of  hypertension continues to be a chal-
lenge. The vast majority of patients will require two or more antihypertensive agents from 
different classes (Hansson et al 1998; Cushman et al 2002; Dahlof et al 2002; Chobanian 
et al 2003), and in attempting to achieve the lower blood pressure target, or where a patient 
has more severe hypertension, three or more antihypertensive agents may be required 
(Chobanian et al 2003). Guidelines recommend initiation of combination therapy when 
diastolic blood pressure (DBP) values are 10 mmHg above the DBP target or if SBP 
is 20 mmHg above the systolic blood pressure (SBP) target (Chobanian et al 2003; Vascular Health and Risk Management 2008:4(6) 1238
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Whitworth 2003) and thus effective and well-tolerated 
combination therapies are required to manage patients who 
fail to respond to antihypertensive monotherapy.
For several years, thiazide diuretics such as hydrochlo-
rothiazide (HCTZ) have been ﬁ  rst-line treatment for hyper-
tension (Psaty et al 1997; Chobanian et al 2003; Psaty et al 
2003), and several ﬁ  xed-dose combinations with other classes 
of antihypertensive agents such as beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, and angiotensin II 
receptor blockers (ARBs) are now available. While the mech-
anism of action for the antihypertensive effect of thiazides 
is not fully elucidated, it is known that they cause indirect 
activation of the renin-angiotensin system (RAS), providing 
a rationale for combining HCTZ with ACE inhibitors and 
ARBs. Thiazides lower blood pressure in patients with vol-
ume-sensitive hypertension, by induction of volume contrac-
tion. Volume contraction is a stimulus for renin release and 
elevation of background RAS activity. A high level of RAS 
activity is necessary for optimal blockade by an ACE inhibitor 
or an ARB. Combining an ARB with HCTZ has been shown 
in clinical studies to increase the antihypertensive efﬁ  cacy 
of both agents compared with either agent alone (Benz et al 
1998; Kochar et al 1999; Dahlof et al 2002). In contrast, while 
the antihypertensive effect of both drugs together is additive, 
a meta-analysis of combination therapy demonstrates that the 
prevalence of adverse events was less than would be expected 
with additive effects (Law et al 2003).
Olmesartan is the most recently introduced ARB, which 
has been shown to produce greater reductions in blood 
pressure than a range of antihypertensive agents including 
other ARBs (Ball et al 2001; Puchler et al 2001; Stumpe and 
Ludwig 2002; Brunner and Laeis 2003). Olmesartan is also 
available as a ﬁ  xed-dose combination with HCTZ. In this 
review, we examine the efﬁ  cacy and safety of olmesartan plus 
HCTZ in a range of clinical cohorts, grouped according to 
study design, duration of treatment, and patient selection.
Clinical efﬁ  cacy
Evidence for the efﬁ  cacy of olmesartan plus HCTZ, and 
the beneﬁ  t of combination treatment over monotherapy 
with either agent, comes from 5 clinical trials. The design 
and features of these trials is shown in Table 1. Four of the 
Table 1 Summary of studies examining the efﬁ  cacy and safety of olmesartan medoxomil plus HCTZ
Study reference Design Entry criteria Primary efﬁ  cacy 
endpoint
Treatment arms/drug 
dosages
Pooled factorial design 
studies (Chrysant et al 2004; 
Daiichi-Sankyo, Integrated 
Summary of Efﬁ  cacy, 
data on ﬁ  le)
Randomized, db, pc, pg, 
mc, factorial design
Mean seDBP 
100–115 mmHg at 
weeks 3 and 4 of 
placebo run-in
Change from baseline in 
mean trough seDBP at 
week 8 or 12
Placebo OLM (10, 20 
or 40 mg/day) HCTZ 
(12.5 or 25 mg/day) 
OLM plus HCTZ 
(all combinations)
HCTZ add-on cohort
(Sellin et al 2005)
Partially randomized, 
db, pc, pg, mc
Mean seDBP 
100–115 mmHg and 
mean 24-hour DBP 
(by ABPM) 84 mmHg; 
30% daytime DBP 
90 mmHg; seDBP 
90 mmHg after 
olmesartan run-in
Change from baseline to 
end of study (week 12) 
in mean daytime DBP 
(by ABPM)
OLM (20 mg/day) OLM 
plus HCTZ (20 mg/day 
plus 12.5 or 25 mg/day
Severe hypertensive cohort 
(Ball et al 2001)
Randomized, db, pg, mc, 
double-dummy, dose-
titration, comparison 
study
Moderate–severe 
essential 1 (seDBP 
100–120 mmHg) at 
end of HCTZ run-in.
Change from baseline in 
mean trough seDBP at 
week 12
OLM plus HCTZ (10 or 
20 mg/day plus 25 mg/day) 
Atenolol plus HCTZ (50 
or100 mg plus 25 mg/day)
Treat-to-target cohort 
(Neutel et al 2004, 2006)
Open-label, 
non-comparative, mc, 
treat-to-target, with 
6-step treatment 
algorithm
Mean seDBP 
90–109 mmHg
Change from study 
baseline/treatment baseline 
to the end of each 4-week 
period using the LOCF 
in seDBP and seSBP and 
number of responders 
(SBP ≤130 mmHg, DBP 
≤85 mmHg).
OLM (20 or 40 mg/day) 
OLM plus HCTZ 
(40 mg/day plus 12.5 or 
25 mg/day) OLM plus 
HCTZ plus amlodipine 
(40 mg/day plus 25 mg/day 
plus 5 or 10 mg/day)
Abbreviations: ABPM, ambulatory blood pressure monitoring; db, double-blind; HCTZ, hydrochlorothiazide; LOCF, last observation carried forward; mc, multicenter; OLM, 
olmesartan medoxomil; pc, placebo-controlled; pg, parallel-group; seDBP, seated diastolic blood pressure; seSBP, seated systolic blood pressure.Vascular Health and Risk Management 2008:4(6) 1239
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studies were randomized, double-blind, multicenter studies 
that examined the efﬁ  cacy of olmesartan alone or in com-
bination with HCTZ using factorial dose-ranging design 
(2 studies); parallel group, HCTZ add-on design (1 study); 
or dose-titration, olmesartan add-on design (1 study). The 
ﬁ  fth study was an open-label, dose-titration treat-to-target 
study in which patients received olmesartan in combination 
with HCTZ and/or amlodipine.
In all studies trough seated and standing blood pressure 
measurements were recorded with a standard mercury sphyg-
momanometer. Where ambulatory blood pressure monitoring 
(ABPM) was used, ABPM was recorded with a Spacelabs 
blood pressure monitor (Spacelabs GmbH, model 90207, 
Kaarst, Germany).
The primary efﬁ  cacy end-point in the factorial studies and 
in the severe hypertension study was the change in trough 
seated DBP (seDBP) from baseline to the end of treatment 
(week 8, week 12, or the last post-baseline observation). Both 
DBP and SBP were measured at weeks 4, 8, and 12 of each 
study. The primary efﬁ  cacy end-point in the HCTZ add-on 
cohort was the change in 24-hour mean ABPM between 
baseline (week 4 of treatment with HCTZ) and the end of 
treatment (week 12).
Each study reported the proportion of responders, deﬁ  ned 
in the factorial studies and the severe hypertension study as 
a mean seDBP 90 mmHg or a decrease of 10 mmHg 
in seDBP at the end of treatment. In the HCTZ add-on 
study, responders were deﬁ  ned as having a mean daytime 
DBP of 85 mmHg as measured by 24-hour ABPM.
In all cases, the last observation carried forward (LOCF) 
method was used to impute missing values and all statistical 
tests were two sided with a p  0.05 deﬁ  ned as statistically 
signiﬁ  cant. In the factorial studies, which included 12 treat-
ment groups, the signiﬁ  cance level in the ANCOVA was 
deﬁ  ned as 0.05 ÷ 12 (ie, p  0.004). ANCOVA was used 
to compare the change from baseline blood pressure (seated 
DBP or 24-hour ABPM) in the different dosage groups in the 
various studies. In the severe hypertension study the combi-
nation of olmesartan/HCTZ was declared to be non-inferior 
to the combination of atenolol/HCTZ if the upper limit of a 
2-sided 95% conﬁ  dence interval (CI) for the difference in 
least-squares means was 3.5 mmHg.
Placebo-controlled factorial 
design studies
The two factorial studies (Chrysant et al 2004; Daiichi-
Sankyo, data on ﬁ  le) were of a sufﬁ  ciently similar design to 
allow pooling and integration of data. This was conducted 
in an Integrated Summary of Efﬁ  cacy, as shown in Table 1 
(Daiichi-Sankyo, Integrated Summary of Efﬁ  cacy, data on 
ﬁ  le). The studies were factorial dose-ranging studies designed 
to identify the optimum combination doses and to show that 
the combination for olmesartan and HCTZ is superior to 
each component alone. Response surface techniques using 
quadratic modeling were also used to model the optimal 
response within the range of experimental doses. Treatment 
was with olmesartan 0, 10, 20, and 40 mg and HCTZ 0, 12.5, 
and 25 mg in all possible combinations.
The total ITT population in these pooled studies com-
prised 1986 patients. Of these, 979 received combination 
therapy; 498 olmesartan/placebo; 344 HCTZ/placebo; and 
165 placebo only. The numbers of patients and their baseline 
characteristics were generally similar among the 12 treatment 
groups and an overview is shown in Table 2. Most patients 
in all treatment groups were Caucasian the mean age ranged 
from 53.4 to 55.3 years, and most patients in all treatment 
groups were 65 years of age.
A dose-dependent decrease from baseline in seDBP was 
seen with respect to both the olmesartan and HCTZ com-
ponents (Figure 1a). Combination treatment with the higher 
doses of each monotherapy component produced substantial 
decreases from baseline in seDBP, with reductions of 19.6 
and 20.1 mmHg seen when olmesartan 20 mg and 40 mg, 
respectively were added to HCTZ 25 mg. All combinations 
of olmesartan/HCTZ were significantly more effective 
compared with the respective dose of HCTZ monotherapy 
(Figure 1c) and all combinations of olmesartan/HCTZ 25 mg 
were signiﬁ  cantly more effective than the respective dose of 
olmesartan monotherapy (Figure 1c).
Decreases from baseline in seSBP at the primary endpoint 
paralleled those of seDBP, although reductions in mean 
seSBP were generally greater than the reductions in mean 
seDBP. The reductions were mainly dose-related for both 
olmesartan and HCTZ components (Figure 1b). Combination 
treatment with the higher doses of each component produced 
substantial decreases from baseline in seSBP, with reductions 
of at least 26 mmHg seen when olmesartan 20 mg and 40 mg, 
respectively were added to HCTZ 25 mg.
For both seDBP and seSBP, the effects of olmesartan and 
HCTZ were additive, which was conﬁ  rmed using response 
surface modeling. When the analysis was restricted to the 
range of doses tested, the optimal dose of olmesartan/HCTZ 
for SBP reductions was estimated to be 27.1 mg/24.2 mg 
(estimated to produce a mean decrease of 27.6 mmHg) and 
for DBP reduction was estimated to be 27.6 mg/24.1 mg (esti-
mated to produce a mean decrease of 20.6 mmHg). In practical Vascular Health and Risk Management 2008:4(6) 1240
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terms, the optimal dose corresponds to the olmesartan/HCTZ 
20 mg/25 mg and 40 mg/25 mg combinations.
The proportion of patients with a treatment response was 
higher for combination therapy than with either component 
alone (Table 3). Response rates were consistently higher in 
patients receiving olmesartan/HCTZ combination therapy 
than in those receiving the same respective doses of olmes-
artan or HCTZ with placebo. Among patients treated with 
olmesartan/HCTZ 20 mg/25 mg or 40 mg/25 mg, more than 
90% of patients were responders.
HCTZ add-on study
Conventional blood pressure measurements may be affected 
by so-called ‘‘white-coat hypertension’’ (Pickering et al 
1988), in which a patient’s anxiety may cause increases in 
blood pressure during monitoring in the clinic. Ambulatory 
blood pressure monitoring (ABPM) may offer a more accu-
rate picture of a patient’s blood pressure over the course of 
the day, and may therefore further demonstrate the efﬁ  cacy 
of an antihypertensive agent over a 24-hour period (O’Brien 
et al 2003).
The effect of adding either 12.5 mg or 25 mg HCTZ 
to olmesartan 20 mg on ABPM in patients whose DBP 
(measured by standard mercury sphygmomanometer) con-
tinued to be 90 mmHg after 4 weeks of treatment with 
olmesartan 20 mg monotherapy was assessed in a partially 
randomized, placebo-controlled trial (Sellin et al 2005). 
The ITT population comprised 535 individuals, with a total 
of 174, 184 and 177 patients randomized to the olmesartan 
20 mg/placebo, olmesartan 20 mg/HCTZ 12.5 mg and 
olmesartan 20 mg/HCTZ 25 mg groups, respectively.
Table 2 Comparison of demographic and baseline characteristics across studies assessing olmesartan and HCTZ
Study No. patients Mean age 
(years)
Sex
(% male)
Ethnicity
(% caucasian)
Hypertension 
history (years)
Mean baseline seated BP
SBP DBP
Pooled factorial design 
studies (Chrysant et al 
2004; Daiichi-Sankyo, 
Integrated Summary of 
Efﬁ  cacy, data on ﬁ  le)
1986 53.4–55.3 52.1% 93.5% 6.8–7.6 157.2–160.7a 103.6–104.3a
HCTZ add-on cohort 
(Sellin et al 2005)
535 52–54 55.0% 100% 6.9–7.2 147.4–150.4a 95.3–95.8a
Severe hypertensive 
cohort (Ball et al 2001)
328 55.4–55.6 47.9% 100% 6.2–6.8 160.9–161.7a 104.9–105.3*
Treat-to-target cohort 
(Neutel et al 2004; Neutel 
et al 2006)
198 52.8 65.2% 73.7% 8.3 161.2 96.6
Abbreviations: DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure.
*mean for each treatment group (lowest and highest mean values).
Additional analysis of data from this study in the 
Integrated Summary of Efﬁ  cacy described above has deter-
mined that at baseline the mean daytime DBP as measured 
by 24-hour ABPM ranged from 88.3 mmHg to 89.5 mmHg 
across the three treatment groups (Daiichi-Sankyo, Integrated 
Summary of Efficacy, data on file). After 12 weeks of 
treatment the mean change in daytime DBP (the primary 
outcome) was signiﬁ  cantly greater in patients treated with 
either olmesartan/HCTZ 20 mg/12.5 mg (−2.67 mmHg; 
p = 0.01) or 20 mg/25 mg (−4.56 mmHg; p  0.0001) 
than with olmesartan 20 mg/placebo (Table 4). Consistent 
with the primary outcome, the combination of olmesartan 
20 mg/HCTZ 25 mg produced statistically signiﬁ  cant reduc-
tions in night-time DBP (p = 0.0011), and in both daytime and 
night-time SBP and 24-hour DBP and SBP (all p  0.0001) 
compared with olmesartan/placebo 20 mg.
Signiﬁ  cant differences between the combination therapy 
groups and monotherapy was also demonstrated using conven-
tional blood pressure measurement. After 12 weeks of treat-
ment, reductions in mean trough seated DBP (p = 0.001) and 
SBP (p = 0.0002) were signiﬁ  cantly greater with olmesartan 
20 mg/HCTZ 25 mg than with olmesartan/placebo.
The proportion of responders was greatest in patients 
treated with olmesartan 20 mg/HCTZ 25 mg (70.7%) 
or olmesartan 20 mg/HCTZ 12.5 mg (58.6%) than with 
olmesartan/placebo (49.4%).
Once again, olmesartan and HCTZ were demonstrated 
to have additive effects. The use of ABPM conﬁ  rmed that 
olmesartan/HCTZ provides effective control throughout the 
24-hour dosage interval, including during the early hours of the 
morning when the risk of cardiovascular events is highest.Vascular Health and Risk Management 2008:4(6) 1241
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Figure 1 Change from baseline to end-point in (a) least squares mean (LSM) trough seated diastolic blood pressure (DBP) (b) LSM trough seated systolic blood pressure 
(SBP) and (c) treatment differences for change from baseline in DBP for dose comparisons: integrated analysis of two factorial studies.
Abbreviation: HCTZ, hydrochlorothiazide.
Severe hypertension cohort
Moderate to severe hypertension (SBP 160 and/or 
DBP 100) (Mancia et al 2007; Whitworth 2003) not 
only puts patients at greater risk for cardiovascular events, 
but is also more difﬁ  cult to treat, with almost all patients 
requiring 2 or more antihypertensive agents. In 328 patients 
with moderate to severe essential hypertension, the efﬁ  cacy 
of a combination of olmesartan and HCTZ was compared 
Table 3 Percentage of patients with a treatment response in the 
combined factorial studies
OLM (mg)
HCTZ (mg) 0 10 20 40
0 60.4% 79.5% 78.4% 81.1%
12.5 69.8% 89.7% 88.1% 92.7%
25 76.9% 95.6% 94.1% 92.7%
Abbreviations: HCTZ, hydrochloroziazide; OLM, olmesartan medoxomil.
with atenolol in a non-inferiority, dose titration study (Ball 
et al 2001). A 4-week single-blind placebo run-in phase 
was followed by single-blind treatment with HCTZ 25 mg 
for 4 weeks. Patients whose DBP was 100–120 mmHg 
after 4 weeks of HCTZ monotherapy were randomized to 
12 weeks’ treatment with olmesartan 10 mg/HCTZ 25 mg 
(n = 164) or atenolol 50 mg/HCTZ 25 mg (n = 164). If mean 
seated DBP was 90 mm Hg and/or the decrease in mean 
seated DBP from baseline was 10 mm Hg after 4 weeks’ 
combination therapy, the dose of olmesartan or atenolol was 
doubled (ie, patients received olmesartan 20/HCTZ 25 mg 
or atenolol 100 mg/HCTZ 25 mg for the ﬁ  nal 8 weeks of the 
treatment phase).
At baseline mean trough seated SBP/DBP was 
160.9/104.9 mm Hg and 161.7/105.3 mmHg in patients 
randomized to olmesartan/HCTZ and atenolol/HCTZ, 
respectively (Daiichi-Sankyo, Integrated Summary of Efﬁ  -
cacy, data on ﬁ  le).
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Table 4 Comparison of 24-hour ABPM values: change from baseline to week 12 – HCTZ add-on study
Olmesartan 20 mg
Placebo HCTZ 12.5 mg HCTZ 25 mg
Daytime DBP LSM (95% CI) –2.22 (–3.71, –0.73) –4.89 (–6.34, –3.45) –6.78 (–8.26, –5.30)
Night-time DBP LSM (95% CI) –2.79 (–4.23, –1.35) –4.28 (–5.69, –2.87) –6.08 (–7.52, –4.65)
24-hour DBP LS mean (95% CI) –2.62 (–3.94, –1.29) –4.75 (–6.04, –3.46) –6.58 (–7.90,–5.27)
Daytime SBP LSM (95% CI) –2.96 (–5.21, 0.72) –8.00 (–10.17, –5.83) –11.70 (–13.94, (–9.47)
Night-time SBP LSM (95% CI) –3.49 (–5.66, –1.32) –7.22 (–9.33, –5.11) –10.89 (–13.05, –8.74)
24-hour SBP LSM (95% CI) –3.32, (–5.40, –1.24) –7.74 (–9.76, –5.73) –11.37, (–13.44, –9.30)
Abbreviations: ABPM, ambulatory blood pressure monitoring; CI, conﬁ  dence intervals; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; LSM, least squares mean; 
SBP, systolic blood pressure.
After 12 weeks of treatment, the proportion of 
responders was 88.7% and 86.3%, respectively among 
those treated with olmesartan/HCTZ and atenolol/HCTZ. 
The least squares mean reduction in trough seated 
SBP/DBP was –21.1/–17.6 mmHg with olmesartan/
HCTZ and –20.3/–17.5 mmHg with atenolol/HCTZ. 
The upper limit of the 95% CI for the difference in least 
squares means of DBP in the two treatment groups was 
1.18 mmHg. This was below the 3.5 mmHg deﬁ  ned as the 
non-inferiority limit, and so the combination of olmesartan 
(titrated up to the optimal dose of 20 mg) and HCTZ was 
shown to be at least as effective as atenolol (titrated up 
to the maximal dose of 100 mg) plus HCTZ in terms of 
lowering DBP (Daiichi-Sankyo, Integrated Summary of 
Efﬁ  cacy, data on ﬁ  le).
Treat-to-target study
The majority of trials of antihypertensive agents concentrate on 
the mean reductions in blood pressure. However, many patients 
who respond to therapy (ie, have a reduction from baseline 
in DBP) may not achieve the target BP of 140/90 mmHg 
(or 130/85 for high-risk patients) (Chobanian et al 2003; 
Mancia et al 2007). The efﬁ  cacy of olmesartan as part of a 
forced titration algorithm that involved 6 sequential treat-
ment steps, each of 4 weeks’ duration, to achieve a target BP 
of 130/85 mmHg has been assessed (Neutel et al 2004; 
Neutel et al 2006). As part of this algorithm, patients not only 
received olmesartan in combination with HCTZ, but also as 
part of a triple combination with HCTZ and amlodipine.
The algorithm was as follows: olmesartan 20 mg, 
olmesartan 40 mg, olmesartan/HCTZ 40 mg/12.5 mg, 
olmesartan/HCTZ 40 mg/25 mg, olmesartan/HCTZ/
amlodipine 40 mg/12.5 mg/5 mg, and olmesartan/HCTZ/
amlodipine 40 mg/12.5 mg/10 mg. Treatment at each step 
was continued for 4 weeks and if the patient had not reached 
the goal BP, they advanced to the next step.
In a further analysis of the data derived from this study, 
mean changes from treatment baseline were calculated for 
DBP and SBP using observations before each step in the algo-
rithm, and are demonstrated in Figure 2a and b (Daiichi-Sankyo, 
Integrated Summary of Efficacy, data on file). Further 
analysis examining the proportion of patients achieving the 
target blood pressure of 140/90 mmHg showed that at the 
end of the second step, when the maximal dose of olmesartan 
was being used, 57.5% of the 198 patients had reached target. 
At the end of the 4th treatment step, when the maximum doses 
of olmesartan and HCTZ were being used, the proportion of 
patients who had reached the 140/90 mmHg target was 
82.1%. When the analysis used the more stringent target 
of 130/85 mmHg, the proportion of patients who had 
reached target at the end of the second and fourth steps was 
33.0 and 65.4%, respectively (Figure 2c) (Daiichi-Sankyo, 
Integrated Summary of Efﬁ  cacy, data on ﬁ  le). The addition of 
amlodipine produced further reductions in BP so that by the 
end of the sixth treatment step (study end), when the maxi-
mum dose of all three agents was being used, the proportion 
of patients achieving the 140/90 and 130/85 mmHg 
goals was 92.7 and 83.8%, respectively.
Given the estimate that only around one-third of patients 
have their blood pressure controlled to below 140/90 mmHg 
(Chobanian et al 2003), the use of a stepped treatment 
approach such as this where over 90% of all patients, and 
more than 95% of patients with stage 1 hypertension (Daiichi-
Sankyo, Integrated Summary of Efﬁ  cacy, data on ﬁ  le) may 
reach this level shows great potential.
Long-term studies
Since patients with hypertension may require ongoing therapy, 
the ability of olmesartan in combination with HCTZ to pro-
vide effective blood pressure reduction over the long term has 
also been evaluated. A total of 1190 of the 1986 randomized 
patients who were responders in one of the placebo-controlled Vascular Health and Risk Management 2008:4(6) 1243
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factorial studies (Daiichi-Sankyo, Integrated Summary of 
Efﬁ  cacy, data on ﬁ  le) entered a 40-week long-term extension 
study, and of these, 74 patients received placebo, 288 patients 
received olmesartan alone, 178 patients received HCTZ alone, 
and 650 patients received combination therapy.
Notable decreases from baseline to last visit were seen 
for all treatment responders, and, as seen in the 12-week 
double-blind phase of the study, these greater decreases were 
seen in the combination therapy groups than in the placebo 
or monotherapy groups (Figure 3). The between-group 
differences were greater for SBP than DBP, and this could 
be expected due to the fact that this cohort of patients was 
permitted to continue in the extension phase only if they were 
already treatment responders.
Patients who received olmesartan/HCTZ 20 mg/25 mg 
or 40 mg/25 mg achieved mean trough seated SBP/DBP 
of 140/90 mmHg at the end of treatment.
The second placebo-controlled factorial study 
(Chrysant et al 2004) allowed patients to continue 
receiving open-label treatment for 4 months with Vascular Health and Risk Management 2008:4(6) 1245
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olmesartan/HCTZ 20 mg/12.5 mg, titrating HCTZ to 
25 mg in 53/340 patients whose blood pressure was poorly 
controlled on the lower dose (Daiichi-Sankyo, Integrated 
Summary of Efficacy, data on file). Blood pressure was 
reduced in patients receiving both treatment regimens, 
to a mean of 128.1/83.2 in patients receiving the lower 
dose of HCTZ and to a mean of 138.6/91.9 in patients 
requiring HCTZ 25 mg.
The long-term extension results from these two studies 
demonstrate that the blood pressure lowering effects of 
combination therapy are maintained over time, and reiterate 
the additive effects of olmesartan and HCTZ.
Safety
An Integrated Summary of Safety was conducted in order to 
analyze the adverse events that occurred during the studies 
listed above (Daiichi-Sankyo, Integrated Summary of Safety, 
data on ﬁ  le). In the placebo-controlled factorial studies, diz-
ziness was the most commonly reported adverse event in 
patients receiving olmesartan/HCTZ combination therapy, 
although no adverse event was signiﬁ  cantly more frequent 
than another. Interestingly, dizziness became less common 
over time, as patients who continued into the long-term 
extension phase reported fewer incidences.
In the HCTZ add-on study, the incidence of adverse events 
was low, with 6.1%–6.6% of patients reporting at least one 
adverse event across the treatment groups. A total of 6 patients 
in this study withdrew from the study due to adverse events, 
all of whom were receiving olmesartan monotherapy. These 
ﬁ  ndings suggest that the addition of HCTZ to olmesartan does 
not increase the incidence of adverse events.
In the severe hypertensive cohort, patients receiving 
olmesartan/HCTZ combination therapy experienced fewer 
adverse events than patients receiving the atenolol/HCTZ 
combination (34.8 versus 37.2%). Events such as headache, 
dizziness and vertigo were more frequent in the olmesartan/
HCTZ group. Although 2 patients in the olmesartan/HCTZ 
group compared with 1 patient in the atenolol/HCTZ group 
experienced a treatment emergent severe adverse event, 
none of these events were considered to be related to study 
medication.
The pattern was again similar in the treat-to-target 
cohort, in which the overall incidence of treatment emergent 
adverse events was about 40%. Most of these events were 
considered unrelated to the study medication, and were mild 
or moderate.
Across all the studies described here, 44% of patients on 
combination therapy, 49% of placebo patients, 41% of  HCTZ 
patients and 47% of olmesartan patients reported treatment-
emergent adverse events (Daiichi-Sankyo, Integrated Sum-
mary of Safety, data on ﬁ  le). Most adverse events were mild 
or moderate in nature, with only 6% of events reported as 
severe. Overall, 20% of adverse events were considered to be 
treatment related. The frequencies of discontinuations due to 
adverse events were similar across olmesartan monotherapy 
(2.7%), HCTZ monotherapy (3.2%), combination therapy 
(2.3%) and placebo groups (3.0%). Four patient deaths were 
recorded in one of the placebo-controlled factorial studies, 
but only one of these was considered possibly related to study 
medication. Overall, the proportion of adverse events consid-
ered to be treatment related, and the low proportion of severe 
adverse events reported indicate that olmesartan and HCTZ 
are well-tolerated therapies, alone and in combination.
Discussion
The clinical studies included in this review demonstrate that 
olmesartan combined with HCTZ provides a high degree 
of clinical efﬁ  cacy combined with good tolerability. Dose-
ranging data have demonstrated that the combination of 
olmesartan and HCTZ produces dose-dependent increases 
in BP-reducing efﬁ  cacy (Daiichi-Sankyo, data on ﬁ  le). This 
review provides further evidence of this by combining data 
from two dose-ranging studies that used a similar factorial 
design and methodology. The add-on study was included 
since it demonstrates the effect of adding HCTZ to patients 
already receiving olmesartan and the treat-to-target study 
is important since it illustrates that a stepped approach to 
antihypertensive treatment based upon olmesartan and HCTZ 
can increase the numbers of patients who achieve BP targets. 
The study in patients with moderate-to-severe hypertension 
was included to illustrate the efﬁ  cacy of the combination in 
these harder-to-treat patients.
With the large number of patients worldwide whose 
hypertension remains poorly controlled, there is a clear 
clinical need for effective and well-tolerated therapies that 
combine different antihypertensive agents. In fact more than 
two-thirds of patients with hypertension will require com-
bination therapy with two or more antihypertensive agents 
from different drug classes to achieve target blood pressure 
(Cushman et al 2002; Chobanian et al 2003). Thiazide 
diuretics such as HCTZ continue to form the foundation of 
anti-hypertensive therapy and their mechanism of action 
is complementary to that of ARBs, enhancing the efﬁ  cacy 
of both agents. This effect is demonstrated in the pooled 
data from the two factorial studies that demonstrate that the 
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are additive, in that combination therapy with olmesartan 
and HCTZ is signiﬁ  cantly better than monotherapy with 
either drug, except when low-dose combinations are used. 
In addition, the percentage of patients responding to therapy 
(10 mmHg decrease from baseline) is higher in patients 
receiving combination therapy than in those receiving mono-
therapy, and decreases from baseline in both DBP and SBP 
are dose related.
The ﬁ  ndings of the studies described in this review are 
supported by other studies in which the efﬁ  cacy of olmesartan 
in combination with HCTZ has been assessed (Barrios et al 
2007; Kereiakes et al 2007). In the OLMEBEST study, 
patients with mild-to-moderate hypertension who had a 
DBP 90 mmHg after 8 weeks of open label treatment with 
olmesartan 20 mg randomly received olmesartan 40 mg or 
olmesartan 20 mg/HCTZ 12.5 mg for a further 4 weeks. 
Each randomized treatment led to a further reduction in BP 
beyond that produced by the open label treatment. At the end 
of the randomized treatment phase, patients who had received 
olmesartan 20 mg/HCTZ 12.5 mg showed larger a change in 
SBP and DBP (−10.8 and −7.9 mmHg, respectively) than the 
olmesartan 40 mg group (−5.3 and −5.1 mmHg), although 
these differences were not signiﬁ  cant (Barrios et al 2007). 
In addition, a forced titration regimen beginning with olmes-
artan monotherapy (20 followed by 40 mg) followed by the 
addition of HCTZ (12.5 followed by 25 mg) was compared 
with forced titration based upon benazepril monotherapy 
(10 followed by 20 mg) to which amlodipine (5 followed 
by 10 mg) was added (Kereiakes et al 2007). At study end, 
the olmesartan/HCTZ group showed a signiﬁ  cantly larger 
change in SBP (−32.5 mmHg; primary endpoint) than the 
the benazepril/amlodipine group (−26.5 mmHg, p = 0.024). 
Also, a signiﬁ  cantly greater proportion of patients achieved 
the BP goals of 140/90, 130/85, and 130/80 mmHg (66.3, 
44.9, and 32.6%, respectively) with olmesartan/HCTZ com-
pared with the benazepril/amlodipine group (44.7, 21.2, and 
14.1%) (Kereiakes et al 2007).
When given as monotherapy, olmesartan produces greater 
reductions in blood pressure than a range of other agents in 
this class (Brunner and Laeis 2003). While this current review 
does not compare the combination of olmesartan and HCTZ 
with other ARB/HCTZ combinations, previous studies have 
been conducted examining the efﬁ  cacy of other ARBs in 
combination with HCTZ. Candesartan, telmisartan, losartan 
and valsartan have all been used in combination with HCTZ, 
and have demonstrated blood pressure lowering in the range of 
4.5–9 mmHg for DBP and in the range of 6.8–12.6 mmHg for 
SBP, compared with monotherapy regimens (Campbell et al 
2001; Lacourciere et al 2001; Waeber et al 2001; Lacourciere 
and Poirier 2003; Lacourciere et al 2003; Watanabe et al 
2006). A published systematic review examining factorial 
design trials of ARBs combined with HCTZ demonstrated 
that after 8 weeks of therapy, olmesartan plus HCTZ achieved 
the greatest reductions in DBP and SBP when compared with 
irbesartan/HCTZ, telmisartan/HCTZ, and valsartan/HCTZ 
(Ram 2004). While such a review of the literature is limited 
due to inherent differences in the design of the factorial 
studies as well as the lack of statistical analysis of ﬁ  ndings, 
it does demonstrate the efﬁ  cacy of ARB/HCTZ combina-
tions in general, and supports further research in the form of 
head-to-head trials. A recently published meta-analysis of the 
antihypertensive efﬁ  cacy of ARBs in studies using 24-hour 
ABPM found differences in both the magnitude and duration 
of antihypertensive activity between ARBs (Fabia et al 2007). 
Although the analysis was not designed to determine which 
ARB had the greatest efﬁ  cacy, the data presented showed 
that BP reductions were generally greater with olmesartan, 
including in the critical last four hours of the interdose period. 
This review also demonstrated that adding HCTZ to ARBs 
provided further additional reduction in BP.
The results presented here demonstrate that olmesartan is 
highly effective when added to ongoing HCTZ monotherapy 
or, conversely, when HCTZ is added to ongoing olmesartan 
monotherapy. Moderate to severe hypertension also responds 
well to olmesartan therapy, and efﬁ  cacy continues to be 
maintained over the long term.
A further analysis of the treat-to-target study has shown 
that in patients with stage 1 hypertension (baseline SBP 
140–159 mmHg or DBP 90–99 mmHg) at the end of the 4th 
treatment step, when the high doses of olmesartan and HCTZ 
were being used, mean trough seated DBP was 90 mmHg 
in 97.5% of patients, and 85 mmHg in 94.9% of patients, 
and 93.7% of patients had achieved a combined BP goal 
of 140/90 mmHg (Neutel et al 2006). In patients with the 
more severe stage 2 hypertension (baseline SBP 160 mmHg 
or DBP 100 mmHg), the respective proportions of patients 
with DBP 90 and 85 mmHg were 95.0 and 81.0% and 
75.0% of patients had achieved the combined BP goal 
of 140/90 mmHg at the end of the 4th treatment step. The 
addition of amlodipine to this stepped treatment protocol 
produced even greater percentages of goal rate achievement 
in each group of patients (Neutel et al 2006).
These goal rate results obtained with olmesartan plus 
HCTZ appear to be reproducible for other ARB combinations. 
The combination of losartan and HCTZ has also been shown 
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rates, although the percentage of patients reaching goal was 
smaller overall (Salerno et al 2004).
The use of ABPM may offer additional benefits in 
measuring BP over a 24-hour period, and may be espe-
cially important in assessing patients at increased risk of 
cardiovascular events (Chobanian et al 2003). As well as 
olmesartan, other ARB/HCTZ combinations have been 
assessed using ABPM (Lacourciere and Poirier 2003; de la 
Sierra et al 2004; Neutel et al 2005; White et al 2006) and 
consistently show that combination therapy results in greater 
decreases from baseline and higher response rates throughout 
the entire 24-hour period than placebo or monotherapy.
While the efﬁ  cacy of olmesartan and HCTZ has been 
proven to be additive, a previous meta-analysis of combina-
tion therapy has demonstrated that the prevalence of adverse 
events was signiﬁ  cantly lower than would be expected with 
an additive effect (Law et al 2003). The studies analyzed 
in this review conﬁ  rm that the combination of olmesartan/
HCTZ is well tolerated, and that the incidence of adverse 
events is similar in combination and monotherapy groups.
Conclusion
Olmesartan plus HCTZ produces additive reductions in blood 
pressure and, when given at the optimal dose 20/25 mg or 
40/25 mg, produces double-digit reductions in DBP and 
SBP. Thus olmesartan/HCTZ is a well-tolerated option for 
patients who fail to respond to monotherapy and as initial 
therapy in those who require large reductions in DBP or SBP 
to achieve goal blood pressure.
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